Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation and Depletion (2019 - 2024)

Allogene Therapeutics' Depreciation and Depletion history spans 6 years, with the latest figure at $3.6 million for Q1 2024.

  • For Q1 2024, Depreciation and Depletion rose 1.37% year-over-year to $3.6 million; the TTM value through Mar 2024 reached $14.2 million, up 0.97%, while the annual FY2023 figure was $14.2 million, 0.67% down from the prior year.
  • Depreciation and Depletion for Q1 2024 was $3.6 million at Allogene Therapeutics, up from $3.5 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $4.2 million in Q4 2021 and bottomed at $1.8 million in Q3 2020.
  • The 5-year median for Depreciation and Depletion is $3.5 million (2023), against an average of $2.9 million.
  • The largest annual shift saw Depreciation and Depletion soared 247.98% in 2020 before it decreased 27.68% in 2022.
  • A 5-year view of Depreciation and Depletion shows it stood at $1.8 million in 2020, then skyrocketed by 130.04% to $4.2 million in 2021, then fell by 27.68% to $3.1 million in 2022, then rose by 13.33% to $3.5 million in 2023, then grew by 2.24% to $3.6 million in 2024.
  • Per Business Quant, the three most recent readings for ALLO's Depreciation and Depletion are $3.6 million (Q1 2024), $3.5 million (Q4 2023), and $3.6 million (Q3 2023).